BIO 101

Drug Profile

BIO 101

Alternative Names: BIO-101; SARCONEOS

Latest Information Update: 04 Apr 2017

Price : $50

At a glance

  • Originator Biophytis
  • Class Obesity therapies
  • Mechanism of Action Proto-oncogene protein c-mas-1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Muscular atrophy
  • Preclinical Obesity

Most Recent Events

  • 27 Mar 2017 Phase-II clinical trials in Muscular atrophy in France, Belgium (PO)
  • 22 Mar 2017 Preclinical trials in Obesity in France
  • 21 Mar 2017 Biophytis plans mid-stage clinical trials of BIO 101 for sarcopenic obesity, in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top